Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists.

Monroig-Bosque PDC, Morales-Rosado JA, Roden AC, Churg A, Barrios R, Cagle P, Ge Y, Allen TC, Smith ML, Larsen BT, Sholl LM, Beasley MB, Borczuk A, Raparia K, Ayala A, Tazelaar HD, Miller R, Kalhor N, Moran CA, Ro JY.

Ann Diagn Pathol. 2019 Apr 24;41:43-50. doi: 10.1016/j.anndiagpath.2019.04.008. [Epub ahead of print]

PMID:
31132651
2.

Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study.

Luo X, Yin S, Yang L, Fujimoto J, Yang Y, Moran C, Kalhor N, Weissferdt A, Xie Y, Gazdar A, Minna J, Wistuba II, Mao Y, Xiao G.

Sci Rep. 2019 May 3;9(1):6886. doi: 10.1038/s41598-019-42845-z.

3.

Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P.

Am J Respir Crit Care Med. 2019 Mar 21. doi: 10.1164/rccm.201806-1178OC. [Epub ahead of print]

PMID:
30896962
4.

Revisiting localized malignant mesothelioma.

Mann S, Khawar S, Moran C, Kalhor N.

Ann Diagn Pathol. 2019 Apr;39:74-77. doi: 10.1016/j.anndiagpath.2019.02.014. Epub 2019 Feb 19. Review.

PMID:
30798074
5.

Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and immunohistochemical study of 8 cases.

Kalhor N, Moran CA.

Hum Pathol. 2019 Apr;86:124-128. doi: 10.1016/j.humpath.2018.11.030. Epub 2018 Dec 8.

PMID:
30537491
6.

Osteoclast-like giant cell-rich carcinomas of the lung: a clinicopathological, immunohistochemical, and molecular study of 3 cases.

Lindholm KE, Kalhor N, Moran CA.

Hum Pathol. 2019 Mar;85:168-173. doi: 10.1016/j.humpath.2018.10.030. Epub 2018 Nov 14.

PMID:
30447297
7.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer.

Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG.

Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21.

8.

Thymomas With a Prominent Alveolar Growth Pattern: A Clinicopathologic and Immunohistochemical Study of 12 Cases.

Kalhor N, Moran CA.

Am J Clin Pathol. 2019 Jan 7;151(2):171-175. doi: 10.1093/ajcp/aqy127.

PMID:
30247496
9.

Incorporation of Cervista Human Papillomavirus 16/18 Assay Into Algorithms for Classifying Human Papillomavirus Status in Formalin-Fixed, Paraffin-Embedded Head and Neck Squamous Carcinoma Specimens.

Guo M, Khanna A, Wang J, Williams MD, Kalhor N, Gong Y, Xu L, Sturgis EM, Staerkel G.

Arch Pathol Lab Med. 2019 Mar;143(3):356-361. doi: 10.5858/arpa.2017-0469-OA. Epub 2018 Sep 17.

PMID:
30221979
10.

Thymic epithelial neoplasms with rhabdomyomatous component: a clinicopathological and immunohistochemical study of 7 cases.

Kalhor N, Moran CA.

Hum Pathol. 2019 Jan;83:100-105. doi: 10.1016/j.humpath.2018.08.027. Epub 2018 Sep 12.

PMID:
30217623
11.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN Jr, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II.

J Immunother Cancer. 2018 Jun 6;6(1):48. doi: 10.1186/s40425-018-0368-0.

12.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
13.

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV.

Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 6.

14.

MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.

Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X.

Oncotarget. 2018 Feb 7;9(16):12959-12970. doi: 10.18632/oncotarget.24430. eCollection 2018 Feb 27.

15.

Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.

Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II.

J Thorac Oncol. 2018 Jun;13(6):779-791. doi: 10.1016/j.jtho.2018.03.002. Epub 2018 Mar 8.

16.

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.

Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.

Cancer Cytopathol. 2018 May;126(5):342-352. doi: 10.1002/cncy.21987. Epub 2018 Mar 2.

17.

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.

Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J.

Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. Epub 2018 Feb 6.

18.

Primary thymic adenocarcinomas: a clinicopathological and immunohistochemical study of 16 cases with emphasis on the morphological spectrum of differentiation.

Kalhor N, Moran CA.

Hum Pathol. 2018 Apr;74:73-82. doi: 10.1016/j.humpath.2018.01.011. Epub 2018 Jan 12.

PMID:
29339175
19.

Pulmonary mucoepidermoid carcinoma: diagnosis and treatment.

Kalhor N, Moran CA.

Expert Rev Respir Med. 2018 Mar;12(3):249-255. doi: 10.1080/17476348.2018.1428563. Epub 2018 Jan 17. Review.

PMID:
29338644
20.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN Jr.

Ann Thorac Surg. 2018 Feb;105(2):418-424. doi: 10.1016/j.athoracsur.2017.08.052. Epub 2017 Dec 6.

Supplemental Content

Loading ...
Support Center